Tissue Plasminogen Activator Activity in Prostatic Cancer

Koller, Antje; Kirchheimer, Johannes C.; Pflüger, Heinz; Br, Binder

doi:10.1159/000463841

Cited by 20 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that fibrinolysis seems to play a prominent role in (metastatic) prostatic carcinoma, as indicated by increased D-dimer levels and increased urokinase-type plasminogen activator levels in the blood of patients with (metastatic) prostatic carcinoma (1,2,9,10). In our patient groups, increased D-dimer levels were found in the treated cancer group with metastases.…”

Section: Discussionsupporting

confidence: 59%

Coagulation and Fibrinolysis Activation Markers in Prostatic Carcinoma Patients

Geenen¹,

Delaere²,

Wersch³

1997

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

In 49 patients with benign prostatic hyperplasia, 24 metastatic prostatic carcinoma patients all under palliative hormonal treatment, 17 untreated prostatic carcinoma patients without metastases and 14 untreated prostatic carcinoma patients with metastases, plasma levels of thrombin-antithrombin III complex, D-dimer and plasmina 2 -antiplasmin were determined.The coagulation activation marker thrombin-antithrombin III complex did not show any significant difference between the different patient groups. Of the fibrinolysis markers, D-dimer levels were elevated in both metastatic groups compared to the non-metastatic group and the benign prostatic hyperplasia group. Surprisingly, the levels of the other fibrinolysis marker, plasmin-a 2 -antiplasmin, showed no significant difference. The nature of these findings is discussed and related to other relevant literature. The general conclusion is that fibrinolysis may not play such a prominent role in prostatic carcinoma as described and expected.

show abstract

Section: Discussionsupporting

confidence: 59%

Coagulation and Fibrinolysis Activation Markers in Prostatic Carcinoma Patients

Geenen¹,

Delaere²,

Wersch³

1997

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…u‐PA is upregulated in a variety of solid malignancies 5, 9, 10. Increased u‐PA expression in vitro has been demonstrated by immunohistochemic studies showing upregulation in clinical CaP specimens11 as well as other tumors and the increased u‐PA expression correlates with the stage and grade of the cancer 12–14. u‐PA was 1.5‐fold higher from the respective bone metastases compared to primary tumors in CaP patients 15.…”

mentioning

confidence: 90%

Regulation of u-PA gene expression in human prostate cancer

et al. 2001

View full text Add to dashboard Cite

“…The expression of PAs, especially uPA and uPAR, and of PAls and Pm inhibitors has been observed in many tumor tissues and tumor cell lines. In contrast to tPA, increased expression of uPA or of uPAR was found to be associated with an unfavorable prognosis in many tumors, including carcinoma of the breast [182][183][184][185][200][201][202][203][204][205], prostate [206][207][208][209][210][211], colon [186,[212][213][214][215][216][217][218][219] and lung [220,221]. In some tumors, such as in carcinoma of the colon, lung and prostate, immunoperoxidase staining of uPA was observed to be heavier in the invading front of the tumor [213,254].…”

Section: Tumor Invasion Growth and Metastasismentioning

confidence: 99%

“…Carcinoma of the prostate [206][207][208][209][210][211]254] Normal prostate tissues and prostatic fluid contain uPA. The amount in carcinomatous prostate is, however, much greater and is more than that found in benign hyperplasia [206].…”

Section: Carcinoma Of the Breast [182-18520and205]mentioning

confidence: 99%

The plasminogen-plasmin system in malignancy

1992

View full text Add to dashboard Cite

The study of the plasminogen-plasmin system has, in the past, contributed much to the understanding of fibrinolysis and thrombolysis. Attention is now focused on the role of the components of this system in many biologic functions. Findings of uPA, its receptor and its inhibitor in many tumor tissues and tumor cell lines, strongly implicate their involvement in tumor invasion, tumor cell proliferation and metastasis. The characteristics of the plasminogen activators, the uPA receptor and the plasminogen activator inhibitors as well as their expression and regulation in tumors and tumor cell lines are reviewed.

show abstract

Tissue Plasminogen Activator Activity in Prostatic Cancer

Cited by 20 publications

References 16 publications

Coagulation and Fibrinolysis Activation Markers in Prostatic Carcinoma Patients

Coagulation and Fibrinolysis Activation Markers in Prostatic Carcinoma Patients

Regulation of u-PA gene expression in human prostate cancer

The plasminogen-plasmin system in malignancy

Contact Info

Product

Resources

About